VTVT · vTv Therapeutics

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

3980 Premier Drive, Suite 310, High Point, NC, 27265, United States
Biotechnology
Healthcare

Market Cap

70.97M

52 Wk Range

$17.28 - $44.00

Previous Close

$17.69

Open

$17.54

Volume

2,710

Day Range

$16.89 - $17.68

Enterprise Value

-19.16M

Cash

77.16M

Avg Qtr Burn

-10.19M

Insider Ownership

38.27%

Institutional Own.

43.30%

Qtr Updated

Sep 30th 2026